For example, despite abundant preclinical evidence for neuroprotective effects of glial cell line-derived neurotrophic factor (GDNF) delivered to the striatum or the SN in animal models of PD, clinical trials in patients with PD have largely failed. This evidence concerns the gene GDNF and Parkinson disease.